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Minireviewp75NTR Is Positively Promiscuous:
Novel Partners and New Insights
p75NTR and the Trks—Old but Not Forgotten
Trks are often termed high-affinity NGF receptors, but




that of p75NTR, with a Kd of about 1–10 nM. However,3801 University Avenue
when the receptors are coexpressed, p75NTR enhancesMontreal, Quebec
the ability of Trk receptors to bind and respond to neuro-Canada, H3A 2B4
trophins and sharpens the discrimination of Trks for
their preferred neurotrophin ligands. Peripheral tissues
produce low concentrations of neurotrophins to main-Although identified almost 20 years ago, the precise
tain appropriate levels of neuronal survival and innerva-physiological role of the p75 neurotrophin receptor
tion, and p75NTR appears to act as a coreceptor that(p75NTR) has remained elusive. Recent studies have
allows the Trks to respond to limiting neurotrophin lev-revealed that p75NTR is a component of three distinct
els. Indeed, the loss of sympathetic and sensory neuronsreceptor platforms that bind different ligands and that,
and the progressive peripheral neuropathy observed inunder differing circumstances, facilitate cell survival,
adult p75NTR null mice (Lee et al., 1992; von Schack etcell death, or growth inhibition. These recent develop-
al., 2001) likely reflect reduced Trk activation in periph-ments provide new insights into the functions of this
eral neurons.enigmatic receptor.
p75NTR and Sortilin—Partners in Crime
Over the last decade, numerous studies have shownThe neurotrophins exert a wide array of effects in the
that p75NTR can act as an apoptotic receptor duringcentral and peripheral nervous system. Originally char-
development and following injury, but there has beenacterized for their survival promoting activity, the four
controversy about the precise ligand requirements formammalian neurotrophins are now implicated in func-
these effects. Mature neurotrophins are not effectivetions that include neuronal growth, apoptosis, and syn-
activators of p75NTR-induced apoptosis, and high non-aptic modulation. At first glance, the receptor system
physiological concentrations are often required to in-that mediates these effects seems simple enough, con-
duce even modest levels of cell death. This led to specu-sisting of the three Trk receptors and the p75 neuro-
lation that there may be other mammalian ligands fortrophin receptor (p75NTR). By and large, the Trk recep-
p75NTR, and several labs initiated searches to try totors behave as typical receptor tyrosine kinases, and
find them. Although one p75NTR binding factor wasdetails of the signaling pathways and cell biology sur-
identified in invertebrates (Fainzilber et al., 1996), it hadrounding their actions have steadily accumulated over
no apparent mammalian homolog, and with this excep-the last several years. In contrast, the precise physiologi-
tion, these searches were uniformly unsuccessful. Thecal roles of the p75NTR have been slow to emerge.
discovery that proneurotrophins (proNTs), which hadHowever, recent studies have shown that p75NTR con-
been under our collective noses all along, were the long-tributes to several different signaling platforms and sug-
sought ligands for p75NTR was an important break-gest that its biological activities have been underesti-
through that was rich in irony.mated (Figure 1).
Neurotrophins are synthesized as precursors that canWhen p75NTR was cloned in 1986, it represented a
be cleaved by furin and proconvertases to produce ma-
novel receptor class that contained tandem arrays of
ture NGF. However, in some tissues, a substantial pro-
cysteine-rich domains (CRDs) in its extracellular portion.
portion of proNGF and proBDNF eludes cleavage, rai-
The CRDs in p75NTR are required for neurotrophin bind- sing the possibility that these uncleaved forms of the
ing and were subsequently recognized as the defining neurotrophin may have biological functions. Using a
characteristic of the tumor necrosis receptor (TNFR) su- furin-resistant form of proNGF, Hempstead and col-
perfamily. TNFR superfamily members typically bind ho- leagues found that proNGF binds p75NTR with high
motrimeric ligands that are produced as type II trans- affinity and is a potent inducer of p75NTR-dependent
membrane proteins, and most act as independent apoptosis in sympathetic neurons, oligodendrocytes,
signaling units. In contrast, p75NTR binds soluble di- and in a vascular smooth muscle cell line (Lee et al.,
meric ligands and often requires (or acts as) a coreceptor 2001; Nykjaer et al., 2004). These investigators also
to activate biological activity. Some TNFR family mem- showed that proNGF does not bind TrkA and suggested
bers, including p75NTR, contain an 80 amino acid that proNGF is an apoptotic ligand that is specific for
death domain; most use the death domain as a protein p75NTR.
binding module to interact with adaptor proteins that The role of proNGF in p75NTR-dependent apoptosis
aggregate and activate Caspase-8 and thereby initiate in vivo has now been examined in two injury paradigms.
apoptosis, but the death domain in p75NTR is structur- Beattie et al. (2002) have shown that oligodendrocyte
ally distinct from that in other TNFR superfamily mem- apoptosis that occurs after spinal cord trauma corre-
bers, and signaling properties of p75NTR are distinct lates with the synthesis of bioactive proNGF, indicating
from its TNFR breathren. Indeed, p75NTR can be consid- that proNGF is in the right place at the right time to
ered the black sheep in the TNFR family. induce cell death in vivo. Corticospinal neurons (CSN)
undergo p75NTR-dependent apoptosis following lesion,
and Harrington et al. (2004) used two loss-of-function*Correspondence: phil.barker@mcgill.ca
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Figure 1. p75NTR Signaling Modules
p75NTR physically interacts with the TrkA re-
ceptor and enhances the ability of TrkA to
respond to NGF and discriminate between
preferred and nonpreferred neurotrophin li-
gands. A second signaling complex con-
sisting of p75NTR and Sortilin mediates pro-
apoptotic signals in response to proNGF
binding. Finally, p75NTR may form a tripartite
complex with the NogoR and with Lingo-1
that results in growth inhibitory signals to be
transduced in response to Nogo, MAG, or
OMgP. CRD, cysteine-rich domain; DD, death
domain; LRR, leucine-rich repeat; IgC2, IgC2
domain; TK, tyrosine kinase domain; VPS10,
VPS10 domain; LRRN, N-terminal leucine-
rich repeat domain; LRRC, C-terminal leu-
cine-rich repeat domain.
approaches to establish a role for proNGF in this system. gene that traffics cargo from the trans golgi network
(TGN) to the vacuole. In mammalian cells, Sortilin hasIn the first, antibodies directed against either mature
NGF or against the prodomain of NGF were shown to been shown to play an important role in TGN-to-endo-
some and TGN-to-lysosome trafficking events, andreduce CSN loss, and in the second, significant protec-
tion of CSNs was observed in mice containing only a greater than 90% of the sortilin pool is retained in intra-
cellular compartments (Nielsen et al., 2001). It is notsingle NGF allele. Importantly, the investigators demon-
strated that p75NTR immunoprecipitated from lesioned known if p75NTR and Sortilin affect each other’s subcel-
lular distribution, but cell surface levels of Sortilin cantissue is bound to proNGF and showed that infusion of
antibodies directed against proNGF reduces this associ- be increased in response to insulin exposure (Morris
et al., 1998). The regulated insertion of neurotrophination. This well-crafted study thus provides direct and
definitive evidence for the participation of proNGF in receptors has been previously documented, and it is
plausible that regulated insertion of p75NTR-Sortilinp75NTR-dependent cell death in vivo.
How does p75NTR bind and mediate the effects of complexes may also occur, perhaps in response to
stress or neuronal injury.proNGF? Studies that address this question are just
beginning, but the identification of Sortilin as a p75NTR ProNGF directly binds Sortilin, even in the absence of
p75NTR. Since Sortilin plays a role in TGN-to-endosomecoreceptor that is necessary for proNGF-induced cell
death is a major breakthrough (Nykjaer et al., 2004). trafficking, it is possible that Sortilin functions not only
as a cell surface proNT receptor but also directs intracel-Sortilin is a type I transmembrane protein expressed in
a wide variety of tissues but is most abundant in the lular movement of newly synthesized proNTs. BDNF can
be sorted to both constitutive and regulated secretorycentral nervous system during development and in
adults. Nykjaer and colleagues (2004) recently found vesicles, and its prodomain has been shown to play an
important role in these trafficking decisions. In humans,that the NGF prodomain directly binds the extracellular
domain of Sortilin and, through crosslinking studies, es- a polymorphism that results in a single substitution in
the prodomain of BDNF (V66M) blocks trafficking oftablished that p75NTR and Sortilin form a receptor com-
plex that binds proNGF at the cell surface. Both recep- BDNF from TGN to secretory granules and is associated
with deficits in episodic memory (reviewed in Lu, 2003).tors appear to be required to transduce the apoptotic
effects of proNGF. Blocking the interaction of proNGF The precise molecular mechanism that leads to this se-
cretory defect is unknown, but one possibility is that thewith Sortilin inhibits proNGF-mediated apoptosis,
whereas expression of exogenous Sortilin in Schwann V66M substitution increases the affinity of BDNF for
Sortilin and thereby prevents its trafficking to regulatedcells, which normally express only p75NTR, renders
these cells sensitive to the apoptotic effect of proNGF secretory vesicles. The functional roles of the other
VPS10 proteins expressed in humans (Figure 2) are(Nykjaer et al., 2004). Interestingly, although p75NTR
and Sortilin are required for proNGF-induced apoptosis, largely uncharacterized, and it may be worthwhile to
determine if any of these physically or functionally inter-their coexpression does not invariably result in proNGF-
induced killing; for example, proNGF does not induce act with p75NTR or the proNTs.
Most studies that have examined p75NTR-inducedapoptosis of melanoma cells but instead enhances mi-
gratory activity (Shonukan et al., 2003). apoptosis suggest that p75NTR induces an intrinsic
apoptotic cascade that involves Rac1 and JNK activa-Like p75NTR, Sortilin leads a complicated life. Sortilin
is a member of the VPS10 family, named for the yeast tion, release of cytochrome C and SMAC from mitochon-
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p75NTR played a role in MBGI-induced growth inhibi-
tion. Consistent with this, they found that MAG-induced
growth inhibition and RhoA activation were attenuated
in sensory and cerebellar granule neurons (CGNs) de-
rived from p75NTR null mice (Yamashita et al., 2002).
The MBGIs bind to the Nogo receptor (NogoR), a GPI-
linked protein with no intracellular signaling capability,
and the discovery that p75NTR played a role in MAG
signaling suggested that p75NTR may collaborate with
the NogoR to mediate responses to MBGIs. Two groups
have independently confirmed this prediction and
shown that a complex containing NogoR and p75NTR
can be identified in cells coexpressing the two receptors
(Wang et al., 2002; Wong et al., 2002).
The precise signaling mechanisms that are activated
by the p75NTR-NogoR complex are now the subject of
intense scrutiny. Initial studies indicated that p75NTR
directly binds and regulates RhoA, but more recent anal-
yses have shown that p75NTR regulates RhoA by di-
rectly binding Rho GDP dissociation inhibitor  (Rho-
GDI). Binding of MBGIs to the p75NTR-NogoR complex
appears to enhance the association of Rho-GDI with
p75NTR, whereas NGF binding abolishes the p75NTR-
RhoGDI interaction (Yamashita and Tohyama, 2003).
In a clever set of experiments, Yamashita and Tohyama
(2003) took advantage of a p75NTR death domain bind-
ing peptide that binds the p75NTR death domain. This
peptide blocks the association of Rho-GDI with p75NTR
in vitro and was shown to antagonize Nogo- and MAG-
induced growth inhibition when delivered to primary
Figure 2. The Mammalian VPS10 Family
sensory neurons. Thus, the association of MBGIs with
Domain structures of each of the receptors are indicated. The VPS10
the p75NTR-NogoR complex causes Rho-GDI to binddomains extend into the TGN lumen or, in the small percentage of
the p75NTR death domain and causes RhoA-GDP to beprotein that reaches the cell surface, are extracellular. PKD domains
released from Rho-GDI. RhoA is then able to exchangedefine an Ig-like region, and LDL-A/LDL-B and FN-III repeats are
conserved motifs originally identified in the low-density lipoprotein bound GDP for GTP and thus gain its active conforma-
receptor and in fibronectin, respectively. tion (Figure 3). Earlier work of Yamashita and colleagues
that showed that unliganded p75NTR was a potent acti-
vator of RhoA could be explained if the association of
dria, and activation of caspase 9, 6, and 3 (Figure 2).
Rho-GDI with p75NTR is attenuated by NogoR coex-
The link between p75NTR-induced JNK activation and pression, but this has not yet been demonstrated experi-
the mitochondrial effects appears to involve direct JNK- mentally.
dependent phosphorylation of Bad, a BH3 domain-only In the latest development, LINGO-1 (also known as
protein, but proximal aspects of this pathway are not LERN1) has been identified as an essential component
well understood (Bhakar et al., 2003). The identification of the p75NTR-NogoR receptor complex that is required
of proNGF as a p75NTR ligand and the characterization for MBGI signaling. Mi et al. (2004) found that the extra-
of the p75NTR-Sortilin signaling complex will no doubt cellular domain of LINGO-1 binds both NogoR and
usher in a new phase in the analysis of p75NTR signaling. p75NTR and showed that full-length LINGO-1 can be
Nogo  Lingo  Don’t Grow? immunoprecipitated with either NogoR or p75NTR (Mi
For many years after it was cloned, p75NTR was search- et al., 2004). In COS cells, coexpression of all three
ing for a function, but now the receptor seems to be receptors was required for RhoA activation in response
making up for lost time. In addition to its roles as a to OMgP, MAG, or NOGO, indicating that, at least in this
Trk coreceptor and regulator of apoptosis, p75NTR has cell type, LINGO-1 is an essential cofactor required for
recently emerged as a key player in the regulation of MBGI signaling. Interestingly, mutant LINGO-1 lacking
neuronal growth. Definitive data linking p75NTR to this its 38 amino acid intracellular domain inhibits MBGI-
function came from studies of Barde and colleagues induced growth inhibition when expressed in CGNs, in-
who demonstrated that unliganded p75NTR was a po- dicating that this domain may play an important role in
tent activator of RhoA and showed that neurotrophins the assembly, cell surface expression, and/or signaling
could suppress this effect (Yamashita et al., 1999). In of the MBGI receptor complex.
adults, RhoA activation mediates the effects of CNS- LINGO-1 is a member of a four-protein family (the
derived myelin-based growth inhibitors (MBGIs) that in- others are LINGO-2, -3, and -4), all of which are charac-
clude Nogo, myelin-associated glycoprotein (MAG), and terized by extracellular leucine-rich repeats (LRRs) and
oligodendrocyte myelin glycoprotein (OMgP). The dis- an IgC2 domain. The primary function of LRR and IgC2
covery that RhoA could be regulated by p75NTR domains is to mediate protein-protein interactions, but
their role in LINGO-1 function is unknown. There areprompted Yamashita and colleagues to determine if
Neuron
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Figure 3. Putative p75NTR-Induced Signal-
ing Cascades
The proapoptotic signaling events mediated
by proNGF are not yet known (middle), but
earlier studies using cleaved neurotrophins or
p75NTR overexpression paradigms provide
the outlines of a possible p75NTR apoptosis
cascade (left). Upon activation, p75NTR as-
sembles a signaling complex that may in-
clude NRAGE, NRIF, and other adaptors.
Rac1 is activated and leads to activation of
a JNK cascade that results in phosphoryla-
tion of Bad and perhaps other BH3 domain-
only family members that release inhibition
of Bax and Bak (data not shown). Subsequent
release of mitochondrial components that in-
clude SMAC and cytochrome C facilitates
caspase activation. p75NTR mediates RhoA
activation via a direct interaction with Rho-
GDI (right). When the complex is in an unli-
ganded state, Rho-GDI is associated with
inactive Rho-GDP in the cytosol. Binding of
MBGIs to the complex produces a conforma-
tional shift in the complex that allows Rho-
GDI to bind to the fifth helix of the p75NTR
death domain and thereby release RhoA.
Once released from Rho-GDI, RhoA is able
to exchange GDP for GTP and achieve its
active conformation and activate down-
stream substrates. Orange boxes indicate
proteins implicated in p75NTR signaling
through experimentation; blue boxes indicate
potential participants.
relatively few proteins that contain both LRR and Ig-like eral factors may slow progress in this area. First,
p75NTR plays several functional roles, and in manydomains in their extracellular region, and it is noteworthy
that TrkA, TrkB, and TrkC belong to this group (Figure cases, the link between p75NTR deletion and an ob-
served phenotype will be difficult to establish. Second,1). The NogoR does not contain IgC2 domains but does
contain multiple LRRs, and it may be more than a coinci- compensatory mechanisms may complicate analyses
of p75NTR loss-of-function strains. One interesting can-dence that this structural motif is present within three
classes of transmembrane proteins that form physical didate for compensatory effects in null strains is neuro-
trophin receptor homolog 2 (NRH2), a recently identifiedcomplexes with p75NTR. Studies that define the struc-
tural basis for these interactions will likely be a top prior- type I transmembrane protein that lacks the CRDs but
otherwise is remarkably similar to p75NTR (Kanning etity since they will provide insights into the function of
these complexes, could lead to the identification of other al., 2003). NRH2 has recently been shown to physically
interact with TrkA receptors (Murray et al., 2004), and itp75NTR binding partners, and may reveal strategies that
could result in the production of selective p75NTR an- will be interesting to learn if this homolog can also bind
Sortilin, NogoR, or LINGO-1 and participate in the effectstagonists.
Reconciling the recent in vitro data that demonstrate of proNTs and MBGIs. A third factor affecting in vivo
analyses is that there have been complications with thea role for p75NTR in MBGI signaling with in vivo findings
on the role of p75NTR in neuronal growth remains a two strains of p75NTR null mice produced to date (Lee
et al., 1992; von Schack et al., 2001). The strain in whichsignificant challenge. At the moment, there is consider-
able variance between in vivo studies, even when similar exon 3 was targeted has been reported to express a
p75NTR splice variant that lacks CRD2-CRD4 (vonexperimental paradigms are employed. For example,
two studies of adult facial neuron regeneration in Schack et al., 2001). We have been unable to detect this
protein in our analyses of the exon 3 mouse (Paul et al.,p75NTR null mice have revealed increased regeneration
and enhanced functional recovery (see Boyd and Gor- 2004), but nonetheless, caution is warranted. Recent
analyses have shown that the exon 4 targeted straindon, 2001), but others have found that the rate of axonal
elongation was not altered (Gschwendtner et al., 2003). harbors a p75NTR fragment that contains the transmem-
brane and intracellular domain and is capable of activat-In the injured spinal cord, the initial phase of RhoA acti-
vation is dependent upon p75NTR expression (Dubreuil ing p75NTR signaling cascades (Paul et al., 2004; von
Schack et al., 2001). The presence of this product mayet al., 2003), yet p75NTR null mice do not show enhanced
regeneration of lesioned corticospinal neurons or as- explain some differences between the exon 3 and 4
strains. For example, the profound vascular phenotypecending sensory tracts after spinal cord damage (Song
et al., 2004). that is observed in the exon 4 strain may represent a
neomorphic gain-of-function defect resulting from ex-Assessing the precise role of p75NTR in neuronal
growth in vivo will be an interesting challenge, and sev- pression of the aberrant p75NTR fragment. Although
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Boyd, J.G., and Gordon, T. (2001). J. Neurobiol. 49, 314–325.much useful information has been obtained from the
Cosgaya, J.M., Chan, J.R., and Shooter, E.M. (2002). Science 298,strains created to date, a complete understanding of
1245–1248.the physiological effects of the receptor will likely require
Dubreuil, C.I., Winton, M.J., and McKerracher, L. (2003). J. Cell Biol.the creation of new conditional mutants and the genera-
162, 233–243.tion of compound nulls.
Fainzilber, M., Smit, A.B., Syed, N.I., Wildering, W.C., Hermann, vanToo Much of a Good Thing Is Wonderful
der Schors, R.C., Jimenez, C., Li, K.W., van Minnen, J., Bulloch, A.G.,The past decade has seen the p75NTR receptor emerge
Ibanez, C.F., and Geraerts, W.P. (1996). Science 274, 1540–1543.
as a key player in regulating Trk action, in the control
Gschwendtner, A., Liu, Z., Hucho, T., Bohatschek, M., Kalla, R.,
of apoptosis, and in the neuronal growth response. Dechant, G., and Raivich, G. (2003). Mol. Cell. Neurosci. 24, 307–322.
p75NTR continues to turn up in surprising functions, Harrington, A.W., Leiner, B., Blechschmitt, C., Arevalo, J.C., Lee, R.,
and recent studies have identified roles for p75NTR in Morl, K., Meyer, M., Hempstead, B.L., Yoon, S.O., and Giehl, K.M.
myelination (Cosgaya et al., 2002) and in the extension (2004). Proc. Natl. Acad. Sci. USA, in press.
of cortical subplate neurons and establishment of thala- He, X.L., and Garcia, K.C. (2004). Science 304, 870–875.
macortical tracts (McQuillen et al., 2002). An additional Kanning, K.C., Hudson, M., Amieux, P.S., Wiley, J.C., Bothwell, M.,
intriguing finding is that p75NTR undergoes cleavage by and Schecterson, L.C. (2003). J. Neurosci. 23, 5425–5436.
-secretase, which results in release of the cytoplasmic Lee, K.-F., Li, E., Huber, J., Landis, S.C., Sharpe, A.H., Chao, M.V.,
and Jaenisch, R. (1992). Cell 69, 737–749.domain from its transmembrane tether and accumula-
tion in the nucleus (Kanning et al., 2003). The function Lee, R., Kermani, P., Teng, K.K., and Hempstead, B.L. (2001). Sci-
ence 294, 1945–1948.of this released fragment is not yet known, but by anal-
Lu, B. (2003). Learn. Mem. 10, 86–98.ogy with Notch and other receptors that undergo similar
McQuillen, P.S., DeFreitas, M.F., Zada, G., and Shatz, C.J. (2002).cleavage, it is conceivable that the p75NTR intracellular
J. Neurosci. 22, 3580–3593.domain may act as a regulatory component of transcrip-
Mi, S., Lee, X., Shao, Z., Thill, G., Ji, B., Relton, J., Levesque, M.,tional complexes. Finally, in the most recent turn in the
Allaire, N., Perrin, S., Sands, B., et al. (2004). Nat. Neurosci. 7,p75NTR tale, the crystal structure of mature NGF bound
221–228.to p75NTR has been solved, with surprising results. He
Morris, N.J., Ross, S.A., Lane, W.S., Moestrup, S.K., Petersen, C.M.,and Garcia (2004) have shown that binding of dimeric
Keller, S.R., and Lienhard, G.E. (1998). J. Biol. Chem. 273, 3582–
NGF to a single chain of p75NTR results in an allosteric 3587.
change in the NGF dimer that actually prevents interac- Murray, S.S., Perez, P., Lee, R., Hempstead, B.L., and Chao, M.V.
tions with additional p75NTR molecules. Thus, the stoi- (2004). J. Neurosci. 24, 2742–2749.
chiometry of NGF-p75NTR receptor complexes is 2:1, Nielsen, M.S., Madsen, P., Christensen, E.I., Nykjaer, A., Gliemann,
and NGF binding to p75NTR will therefore block, rather J., Kasper, D., Pohlmann, R., and Petersen, C.M. (2001). EMBO J.
20, 2180–2190.than facilitate, the formation of p75NTR dimers. This
finding has broad implication for understanding the ac- Nykjaer, A., Lee, R., Teng, K.K., Jansen, P., Madsen, P., Nielsen,
M.S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T.E., ettions of p75NTR; for example, it suggests that p75NTR
al. (2004). Nature 427, 843–848.is a coreceptor capable of sharing or delivering neuro-
Paul, C.E., Vereker, E., Dickson, K.M., and Barker, P.A. (2004). J.trophin ligand to Trk receptors or Sortilin and raises
Neurosci. 24, 1917–1923.the possibility that RhoA activation induced by p75NTR
Shonukan, O., Bagayogo, I., McCrea, P., Chao, M., and Hempstead,requires the formation of a dimeric receptor complex.
B. (2003). Oncogene 22, 3616–3623.All in all, not bad for a receptor that a decade ago
Song, X.Y., Zhong, J.H., Wang, X., and Zhou, X.F. (2004). J. Neurosci.was thought to be little more than biological flotsam.
24, 542–546.
Moving forward, a top priority will be to refine the signal-
von Schack, D., Casademunt, E., Schweigreiter, R., Meyer, M., Bibel,
ing functions of p75NTR and to begin to place the ac- M., and Dechant, G. (2001). Nat. Neurosci. 4, 977–978.
tions of the receptor in a cell biological context. Concur-
Wang, K.C., Kim, J.A., Sivasankaran, R., Segal, R., and He, Z. (2002).
rently, the various activities of p75NTR that have been Nature 420, 74–78.
observed in vitro will need to be firmly linked to its Wong, S.T., Henley, J.R., Kanning, K.C., Huang, K.H., Bothwell, M.,
physiological roles in vivo using appropriate gain- and and Poo, M.M. (2002). Nat. Neurosci. 5, 1302–1308.
loss-of-function models. Yamashita, T., and Tohyama, M. (2003). Nat. Neurosci. 6, 461–467.
Sorting out the complexities of the actions of p75NTR Yamashita, T., Tucker, K.L., and Barde, Y.A. (1999). Neuron 24,
remains a challenging task, but recent developments 585–593.
suggest that the paradox of p75NTR lies in its promiscu- Yamashita, T., Higuchi, H., and Tohyama, M. (2002). J. Cell Biol.
ity. With the identification of new ligands and corecep- 157, 565–570.
tors for p75NTR, it is becoming increasingly difficult for
the receptor to keep its secrets. Together, these findings
mark the beginning of a new phase of neurotrophin re-
ceptor research that is certain to provide new insights
into nervous system function.
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